Lupin

Lupin Pharmaceuticals, a subsidiary of Lupin, is a transnational pharmaceutical company involved in the dedicated development of generic medications.In August 2020, Lupin Inc entered into an agreement with ForDoz Pharma for granting Lupin the exclusive rights to market and distribute two complex injectable assets in advanced stages of development in the US and its territories.In October 2017, the company acquired Symbiomix Therapeutics for a cash consideration of US $150 million including a US $50 million upfront and other time based payments with sales based contingent payments. The acquisition was funded from internal funds and the transaction was closed on October 11, 2017